AstraZeneca announces positive results from Phase III trial of Lynparza for breast cancer
Biopharmaceutical firm AstraZeneca has announced positive results from its Phase III clinical trial (OlympiAD) of Lynparza (olaparib) to treat patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | HER2 | Pharmaceuticals